Alan H Fairlamb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/64133/publications.pdf

Version: 2024-02-01

272 papers	24,758 citations	9756 73 h-index	8370 147 g-index
287 all docs	287 docs citations	287 times ranked	16330 citing authors

#	Article	IF	Citations
1	Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial. Cell Chemical Biology, 2021, 28, 711-721.e8.	2.5	11
2	Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2021, 12, 1405-1412.	1.3	9
3	Surmounting structural barriers to tackle endemic infectious diseases. Journal of Experimental Medicine, 2021, 218, .	4.2	1
4	Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases. Nature Reviews Drug Discovery, 2021, 20, 799-800.	21.5	2
5	Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T.Âb. brucei hit-compound with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2020, 206, 112668.	2.6	11
6	8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T.Âb. brucei and cruzi. European Journal of Medicinal Chemistry, 2020, 202, 112558.	2.6	15
7	New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi. ACS Medicinal Chemistry Letters, 2020, 11, 464-472.	1.3	8
8	The Q_i Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani. ACS Infectious Diseases, 2020, 6, 515-528.	1.8	23
9	Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase. ACS Infectious Diseases, 2020, 6, 1044-1057.	1.8	11
10	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem, 2019, 14, 1329-1335.	1.6	5
11	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	3.3	94
12	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	3.3	119
13	Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity. ACS Medicinal Chemistry Letters, 2019, 10, 34-39.	1.3	31
14	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	1.8	55
15	Fexinidazole for the treatment of human African trypanosomiasis. Drugs of Today, 2019, 55, 705.	0.7	18
16	Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis. Current Medicinal Chemistry, 2019, 26, 4454-4475.	1.2	41
17	Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome. ACS Infectious Diseases, 2018, 4, 1475-1486.	1.8	1
18	Antitrypanosomatid Pharmacomodulation at Position 3 of the 8â€Nitroquinolinâ€2(1H)â€one Scaffold Using Palladiumâ€Catalysed Crossâ€Coupling Reactions. ChemMedChem, 2018, 13, 2217-2228.	1.6	8

#	Article	IF	Citations
19	Melarsoprol Resistance in African Trypanosomiasis. Trends in Parasitology, 2018, 34, 481-492.	1.5	93
20	Characterisation of a putative glutamate 5â€kinase from Leishmania donovani. FEBS Journal, 2018, 285, 2662-2678.	2.2	8
21	Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
22	8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases. European Journal of Medicinal Chemistry, 2018, 157, 115-126.	2.6	19
23	A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism. Biochemical Journal, 2018, 475, 2593-2610.	1.7	12
24	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature, 2018, 560, 192-197.	13.7	112
25	Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study. European Journal of Medicinal Chemistry, 2018, 155, 135-152.	2.6	19
26	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	13.6	315
27	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infectious Diseases, 2017, 3, 718-727.	1.8	22
28	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. ACS Infectious Diseases, 2017, 3, 34-44.	1.8	45
29	Screening a protein kinase inhibitor library against Plasmodium falciparum. Malaria Journal, 2017, 16, 446.	0.8	12
30	Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania. PLoS Pathogens, 2016, 12, e1005971.	2.1	73
31	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 9672-9685.	2.9	66
32	The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei. Journal of Biological Chemistry, 2016, 291, 24768-24778.	1.6	21
33	The N-myristoylome of Trypanosoma cruzi. Scientific Reports, 2016, 6, 31078.	1.6	20
34	Drug resistance in eukaryotic microorganisms. Nature Microbiology, 2016, 1, 16092.	5.9	118
35	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	2.9	13
36	Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases. Nature Reviews Drug Discovery, 2016, 15, 292-292.	21.5	10

#	Article	IF	Citations
37	Nitroheterocyclic drug resistance mechanisms inTrypanosoma brucei. Journal of Antimicrobial Chemotherapy, 2016, 71, 625-634.	1.3	65
38	Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes. Journal of Antimicrobial Chemotherapy, 2016, 71, 956-963.	1.3	5
39	Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase. PLoS Neglected Tropical Diseases, 2016, 10, e0004714.	1.3	23
40	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ELife, 2016, 5, .	2.8	67
41	Homoserine and quorumâ€sensing acyl homoserine lactones as alternative sources of threonine: a potential role for homoserine kinase in insectâ€stage Trypanosoma brucei. Molecular Microbiology, 2015, 95, 143-156.	1.2	18
42	Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidalâ€“antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 5156-5167.	1.4	14
43	Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?. Lancet, The, 2015, 385, S80.	6.3	21
44	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	13.7	353
45	Arsenic Exposure and Outcomes of Antimonial Treatment in Visceral Leishmaniasis Patients in Bihar, India: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2015, 9, e0003518.	1.3	37
46	TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. Nucleic Acids Research, 2015, 43, D637-D644.	6.5	35
47	Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome. PLoS Neglected Tropical Diseases, 2015, 9, e0004299.	1.3	34
48	Biochemical and genetic characterization ofTrypanosoma cruzi N-myristoyltransferase. Biochemical Journal, 2014, 459, 323-332.	1.7	28
49	Erratum for De Rycker et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2014, 58, 7622-7622.	1.4	1
50	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	2.9	57
51	Norspermidine Is Not a Self-Produced Trigger for Biofilm Disassembly. Cell, 2014, 156, 844-854.	13.5	65
52	The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4699-4706.	1.4	62
53	Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2013, 57, 2913-2922.	1.4	135
54	Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation. Antimicrobial Agents and Chemotherapy, 2013, 57, 901-906.	1.4	50

#	Article	IF	Citations
55	Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19932-19937.	3.3	54
56	<scp>T</scp>rypanosoma brucei (<scp>UMP</scp> synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy. Molecular Microbiology, 2013, 90, 443-455.	1.2	21
57	Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead Paralog. Journal of Biological Chemistry, 2013, 288, 15256-15267.	1.6	44
58	A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes. PLoS Neglected Tropical Diseases, 2012, 6, e1932.	1.3	30
59	The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis. Science Translational Medicine, 2012, 4, 119re1.	5.8	126
60	Genomics decodes drug action. Nature, 2012, 482, 167-169.	13.7	9
61	Chemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosome. Molecular Microbiology, 2012, 86, 51-64.	1.2	30
62	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	2.9	102
63	Quinol derivatives as potential trypanocidal agents. Bioorganic and Medicinal Chemistry, 2012, 20, 1607-1615.	1.4	17
64	Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors. ChemMedChem, 2012, 7, 95-106.	1.6	42
65	Antimicrobial drug discovery. Future Microbiology, 2011, 6, 601-602.	1.0	2
66	Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography. Journal of Medicinal Chemistry, 2011, 54, 6514-6530.	2.9	110
67	Methylglyoxal metabolism in trypanosomes and leishmania. Seminars in Cell and Developmental Biology, 2011, 22, 271-277.	2.3	46
68	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. Current Topics in Medicinal Chemistry, 2011, 11, 1275-1283.	1.0	99
69	Triclosan is minimally effective in rodent malaria models. Nature Medicine, 2011, 17, 33-34.	15.2	17
70	Synthesis and Evaluation of Indatralineâ€Based Inhibitors for Trypanothione Reductase. ChemMedChem, 2011, 6, 321-328.	1.6	19
71	Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductaseâ€...1. ChemMedChem, 2011, 6, 302-308.	1.6	39
72	Optimisation of the Antiâ€Trypanosoma brucei Activity of the Opioid Agonist U50488. ChemMedChem, 2011, 6, 1832-1840.	1.6	7

#	Article	IF	Citations
73	Dissecting the Metabolic Roles of Pteridine Reductase 1 in Trypanosoma brucei and Leishmania major. Journal of Biological Chemistry, 2011, 286, 10429-10438.	1.6	47
74	Antitumor Quinol PMX464 Is a Cytocidal Anti-trypanosomal Inhibitor Targeting Trypanothione Metabolism. Journal of Biological Chemistry, 2011, 286, 8523-8533.	1.6	31
75	Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?. PLoS Neglected Tropical Diseases, 2011, 5, e1227.	1.3	45
76	Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Molecular and Biochemical Parasitology, 2010, 169, 12-19.	0.5	54
77	Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Molecular and Biochemical Parasitology, 2010, 173, 162-164.	0.5	69
78	Identification of a Î¹-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochemical Pharmacology, 2010, 80, 1478-1486.	2.0	69
79	Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase. Analytical Biochemistry, 2010, 396, 194-203.	1.1	23
80	Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice. Molecular Microbiology, 2010, 77, 658-671.	1.2	46
81	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	13.7	272
82	Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2010, 54, 2893-2900.	1.4	112
83	Chemical Validation of Trypanothione Synthetase. Journal of Biological Chemistry, 2009, 284, 36137-36145.	1.6	68
84	Improved Tricyclic Inhibitors of Trypanothione Reductase by Screening and Chemical Synthesis. ChemMedChem, 2009, 4, 1333-1340.	1.6	63
85	Synthesis and Evaluation of 1â€(1â€(Benzo[b]thiophenâ€2â€yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase. ChemMedChem, 2009, 4, 1341-1353.	1.6	45
86	Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei. ChemMedChem, 2009, 4, 2060-2069.	1.6	54
87	Dissecting the essentiality of the bifunctional trypanothione synthetaseâ€amidase in Trypanosoma brucei using chemical and genetic methods. Molecular Microbiology, 2009, 74, 529-540.	1.2	71
88	A comparative study of methylglyoxal metabolism in trypanosomatids. FEBS Journal, 2009, 276, 376-386.	2.2	77
89	Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 1670-1680.	2.9	50
90	One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 4454-4465.	2.9	96

#	Article	IF	Citations
91	Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity. Antimicrobial Agents and Chemotherapy, 2009, 53, 2824-2833.	1.4	67
92	ATPâ€dependent ligases in trypanothione biosynthesis â€“ kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. FEBS Journal, 2008, 275, 5408-5421.	2.2	25
93	Chemical and genetic validation of dihydrofolate reductaseâ€“thymidylate synthase as a drug target in African trypanosomes. Molecular Microbiology, 2008, 69, 520-533.	1.2	63
94	Roles of Trypanothione S -Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials. Antimicrobial Agents and Chemotherapy, 2008, 52, 1359-1365.	1.4	73
95	Leishmania Trypanothione Synthetase-Amidase Structure Reveals a Basis for Regulation of Conflicting Synthetic and Hydrolytic Activities. Journal of Biological Chemistry, 2008, 283, 17672-17680.	1.6	86
96	Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation, 2008, 118, 1301-1310.	3.9	460
97	Structural and mechanistic insights into typeÂII trypanosomatid tryparedoxin-dependent peroxidases. Biochemical Journal, 2008, 414, 375-381.	1.7	24
98	Enzymatic Inhibitory Activity and Trypanocidal Effects of Extracts and Compounds from Siphoneugena densiflora O. Berg and Vitex polygama Cham.. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2008, 63, 371-382.	0.6	16
99	Inhibition of trypanothione reductase and glutathione reductase by ferrocenic 4-aminoquinoline ureas. Arkivoc, 2008, 2008, 52-60.	0.3	7
100	Increased levels of thiols protect antimony unresponsiveLeishmania donovanifield isolates against reactive oxygen species generated by trivalent antimony. Parasitology, 2007, 134, 1679-1687.	0.7	94
101	Bis-Acridines as Lead Antiparasitic Agents: Structure-Activity Analysis of a Discrete Compound Library In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2164-2172.	1.4	26
102	A comparative study of typeâ€ƒI and typeâ€ƒII tryparedoxin peroxidases in Leishmania major. FEBS Journal, 2007, 274, 5643-5658.	2.2	35
103	Target assessment for antiparasitic drug discovery. Trends in Parasitology, 2007, 23, 589-595.	1.5	130
104	Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1422-1427.	1.0	49
105	High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1280-1283.	1.0	40
106	Drug Resistance in Leishmaniasis. Clinical Microbiology Reviews, 2006, 19, 111-126.	5.7	1,374
107	Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. Biochemical Journal, 2006, 393, 447-457.	1.7	72
108	Refinement of techniques for the propagation of Leishmania donovani in hamsters. Acta Tropica, 2006, 97, 364-369.	0.9	21

#	Article	IF	Citations
109	Trypanothione-dependent glyoxalase I in Trypanosoma cruzi. Biochemical Journal, 2006, 400, 217-223.	1.7	48
110	Specificity of the trypanothione-dependent Leishmania major glyoxalase I: structure and biochemical comparison with the human enzyme. Molecular Microbiology, 2006, 59, 1239-1248.	1.2	76
111	Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate. Molecular Microbiology, 2006, 61, 1457-1468.	1.2	57
112	Time-dependent inhibitors of trypanothione reductase: Analogues of the spermidine alkaloid lunarine and related natural products. Bioorganic and Medicinal Chemistry, 2006, 14, 2266-2278.	1.4	31
113	Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Biochemical Pharmacology, 2006, 71, 257-267.	2.0	72
114	Mapping the functional synthetase domain of trypanothione synthetase from Leishmania major. Molecular and Biochemical Parasitology, 2006, 149, 117-120.	0.5	8
115	Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochemical Journal, 2005, 391, 425-432.	1.7	69
116	Very Short and Efficient Syntheses of the Spermine Alkaloid Kukoamine A and Analogs Using Isolable Succinimidyl Cinnamates. Chemistry Letters, 2005, 34, 264-265.	0.7	15
117	Trypanothione biosynthesis in Leishmania major. Molecular and Biochemical Parasitology, 2005, 139, 107-116.	0.5	82
118	Crystallization and preliminary X-ray analysis ofLeishmania majorglyoxalase I. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 769-772.	0.7	10
119	MYST Family Histone Acetyltransferases in the Protozoan Parasite Toxoplasma gondii. Eukaryotic Cell, 2005, 4, 2057-2065.	3.4	42
120	The Genome of the African Trypanosome Trypanosoma brucei. Science, 2005, 309, 416-422.	6.0	1,496
121	Leishmania major Elongation Factor 1B Complex Has Trypanothione S-Transferase and Peroxidase Activity. Journal of Biological Chemistry, 2004, 279, 49003-49009.	1.6	53
122	Trypanothione S-Transferase Activity in a Trypanosomatid Ribosomal Elongation Factor 1B. Journal of Biological Chemistry, 2004, 279, 27246-27256.	1.6	56
123	Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani. Journal of Biological Chemistry, 2004, 279, 39925-39932.	1.6	258
124	A trypanothione-dependent glyoxalase I with a prokaryotic ancestry in Leishmania major. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13186-13191.	3.3	87
125	Two Interacting Binding Sites for Quinacrine Derivatives in the Active Site of Trypanothione Reductase. Journal of Biological Chemistry, 2004, 279, 29493-29500.	1.6	97
126	Chemotherapy of human African trypanosomiasis: current and future prospects. Trends in Parasitology, 2003, 19, 488-494.	1.5	292

#	Article	IF	Citations
127	Properties of trypanothione synthetase from Trypanosoma brucei. Molecular and Biochemical Parasitology, 2003, 131, 25-33.	0.5	57
128	Exploring the potential of xanthene derivatives as trypanothione reductase inhibitors and chloroquine potentiating agents. Tetrahedron, 2003, 59, 2289-2296.	1.0	161
129	Benzofuranyl 3,5-bis-Polyamine derivatives as time-Dependent inhibitors of trypanothione reductase. Bioorganic and Medicinal Chemistry, 2003, 11, 3683-3693.	1.4	27
130	Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nature Immunology, 2003, 4, 485-490.	7.0	215
131	Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochemical Journal, 2003, 369, 529-537.	1.7	92
132	Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei. Journal of Biological Chemistry, 2003, 278, 25919-25925.	1.6	43
133	Bis(glutathionyl)spermine and Other Novel Trypanothione Analogues in Trypanosoma cruzi. Journal of Biological Chemistry, 2003, 278, 27612-27619.	1.6	57
134	Properties of Phosphoenolpyruvate Mutase, the First Enzyme in the Aminoethylphosphonate Biosynthetic Pathway in Trypanosoma cruzi. Journal of Biological Chemistry, 2003, 278, 22703-22708.	1.6	19
135	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Memorias Do Instituto Oswaldo Cruz, 2003, 98, 565-568.	0.8	14
136	A Single Enzyme Catalyses Formation of Trypanothione from Glutathione and Spermidine in Trypanosoma cruzi. Journal of Biological Chemistry, 2002, 277, 35853-35861.	1.6	110
137	Characterization of recombinant glutathionylspermidine synthetase/amidase from Crithidia fasciculata. Biochemical Journal, 2002, 364, 679-686.	1.7	48
138	Regiocontrolled synthesis of the macrocyclic polyamine alkaloid (Â±)-lunarine, a time-dependent inhibitor of trypanothione reductase. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 1115-1123.	1.3	20
139	Metabolic pathway analysis in trypanosomes and malaria parasites. Philosophical Transactions of the Royal Society B: Biological Sciences, 2002, 357, 101-107.	1.8	25
140	A new expression vector for Crithidia fasciculata and Leishmania. Molecular and Biochemical Parasitology, 2002, 120, 195-204.	0.5	63
141	Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead. Amino Acids, 2002, 22, 297-308.	1.2	18
142	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: Substitution of the glycine carboxylic acid group. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2553-2556.	1.0	24
143	Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Molecular Microbiology, 2002, 35, 542-552.	1.2	310
144	Computer assisted design of potentially active anti-trypanosomal compounds. Computational and Theoretical Chemistry, 2002, 584, 95-105.	1.5	14

#	Article	IF	Citations
145	Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.	13.7	3,881
146	Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: Substitution of the glycine part. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 2703-2705.	1.0	19
147	Trypanosoma Cruzitrypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radical Research, 2001, 34, 363-378.	1.5	41
148	Specific peptide inhibitors of trypanothione reductase with backbone structures unrelated to that of substrate: potential rational drug design lead frameworks. Amino Acids, 2001, 20, 145-153.	1.2	15
149	Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2655-2657.	1.0	85
150	Cloning of a pyruvate phosphate dikinase from Trypanosoma cruzi. Molecular and Biochemical Parasitology, 2001, 112, 183-191.	0.5	14
151	Ovothiol and trypanothione as antioxidants in trypanosomatids. Molecular and Biochemical Parasitology, 2001, 115, 189-198.	0.5	171
152	Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei. Molecular and Biochemical Parasitology, 2001, 116, 171-183.	0.5	75
153	Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei , Trypanosoma cruzi and Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1147-1150.	1.0	20
154	Cloning, expression and functional characterisation of a peroxiredoxin from the potato cyst nematode Globodera rostochiensis. Molecular and Biochemical Parasitology, 2000, 111, 41-49.	0.5	104
155	Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochemical Pharmacology, 2000, 59, 615-620.	2.0	27
156	The three-dimensional structure of a Plasmodium falciparum cyclophilin in complex with the potent anti-malarial cyclosporin A. Journal of Molecular Biology, 2000, 298, 123-133.	2.0	39
157	The Structure of Reduced Tryparedoxin Peroxidase Reveals a Decamer and Insight into Reactivity of 2Cys-peroxiredoxins. Journal of Molecular Biology, 2000, 300, 903-916.	2.0	152
158	The High Resolution Crystal Structure of Recombinant Crithidia fasciculata Tryparedoxin-I. Journal of Biological Chemistry, 1999, 274, 25613-25622.	1.6	61
159	Synthesis and enzymology of modifiedN-benzyloxycarbonyl-L-cysteinylglycyl-3,3-dimethylaminopropylamide disulphides as alternative substrates for trypanothione reductase fromTrypanosoma crud: Part 3. Amino Acids, 1999, 17, 175-183.	1.2	4
160	Characterization of protein Ser/Thr phosphatases of the malaria parasite, Plasmodium falciparum: inhibition of the parasitic calcineurin by cyclophilin-cyclosporin complex. Molecular and Biochemical Parasitology, 1999, 99, 167-181.	0.5	64
161	Entamoeba histolytica lacks trypanothione metabolism. Molecular and Biochemical Parasitology, 1999, 103, 61-69.	0.5	29
162	The Biochemical Basis of Arsenicalâ€“Diamidine Crossresistance in African Trypanosomes. Parasitology Today, 1999, 15, 136-140.	3.1	134

#	Article	IF	Citations
163	Renewed Strategies for Drug Development against Parasitic Diseases. Parasitology Today, 1999, 15, 393-394.	3.1	2
164	Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure, 1999, 7, 81-89.	1.6	197
165	Ornithine Decarboxylase Gene Deletion Mutants of Leishmania donovani. Journal of Biological Chemistry, 1999, 274, 3781-3788.	1.6	93
166	Crystallization of RecombinantCrithidia fasciculataTryparedoxin. Journal of Structural Biology, 1999, 126, 76-79.	1.3	5
167	Measurement of Polyamine Transport: Cells in Suspension. , 1998, 79, 149-156.		3
168	The Determination of Polyamines and Amino Acids by a Fluorescamine-HPLC Method. , 1998, 79, 125-130.		5
169	Cloning, expression and reconstitution of the trypanothione-dependent peroxidase system of Crithidia fasciculata1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank and DDJB databases under the GenBank accession numbers AF055913 (tryparedoxin) and AF055914 (tryparedoxin peroxidase).1. Molecular and Biochemical Parasitology, 1998, 96, 111-123.	0.5	51
170	Identification and characterisation of a functional peroxidoxin from Leishmania major1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBankâ„¢ and DDJB databases under the accession number AF069386.1. Molecular and Biochemical Parasitology, 1998, 96, 125-137.	0.5	105
171	An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 811-816.	1.0	45
172	Evidence that trypanothione reductase is an essential enzyme inLeishmaniaby targeted replacement of thetryAgene locus. Molecular Microbiology, 1998, 29, 653-660.	1.2	154
173	Macrocyclic polyamine lactam synthesis by diphenyl ether closure of 23-, 24- and 28-membered rings. Chemical Communications, 1998, , 2335-2336.	2.2	13
174	Phenothiazine Inhibitors of Trypanothione Reductase as Potential Antitrypanosomal and Antileishmanial Drugsâ€. Journal of Medicinal Chemistry, 1998, 41, 148-156.	2.9	148
175	SURFACE RECEPTORS AND TRANSPORTERS OFTRYPANOSOMA BRUCEI. Annual Review of Microbiology, 1998, 52, 745-778.	2.9	102
176	Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and - resistant Trichomonas vaginalis and Tritrichomonas foetus [In Process Citation]. Journal of Antimicrobial Chemotherapy, 1998, 42, 817-820.	1.3	27
177	Cloning and Characterization of the Two Enzymes Responsible for Trypanothione Biosynthesis in Crithidia fasciculata. Journal of Biological Chemistry, 1998, 273, 19383-19390.	1.6	40
178	Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: Effect on parasite intracellular survival. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 5311-5316.	3.3	167
179	Detailed characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochemical Journal, 1998, 334, 437-445.	1.7	44
180	Diamine auxotrophy in a eukaryotic parasite. Biochemical Society Transactions, 1998, 26, 606-609.	1.6	4

#	Article	IF	Citations
181	Rational design of selective ligands for trypanothione reductase fromtrypanosoma cruzStructural effects on the inhibition by dibenzazepines based on imipramine. Journal of Enzyme Inhibition and Medicinal Chemistry, 1997, 12, 161-173.	0.5	35
182	Molecular characterization and expression of Onchocerca volvulus glutathione reductase. Biochemical Journal, 1997, 325, 645-651.	1.7	20
183	Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiophen-4,9-quinones. Bioorganic and Medicinal Chemistry, 1997, 5, 2185-2192.	1.4	55
184	Characterization of the peptide substrate specificity of glutathionylspermidine synthetase from Crithidia fasciculata. Molecular and Biochemical Parasitology, 1997, 84, 25-32.	0.5	19
185	Diamine auxotrophy may be a universal feature of Trypanosoma cruzi epimastigotes. Molecular and Biochemical Parasitology, 1997, 84, 111-121.	0.5	71
186	Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO Journal, 1997, 16, 2590-2598.	3.5	272
187	Fluphenazine photoaffinity labelling of binding sites for phenothiazine inhibitors of trypanothione reductase. Chemical Communications, 1996, , 973.	2.2	4
188	Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes. Biochemical Journal, 1996, 316, 481-486.	1.7	65
189	Phosphonic acid and phosphinic acid tripeptides as inhibitors of glutathionylspermidine synthetase. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 253-258.	1.0	39
190	The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 Ã... resolution. Protein Science, 1996, 5, 52-61.	3.1	89
191	Extrachromosomal, homologous expression of trypanothione reductase and its complementary mRNA in Trypanosoma cruzi. Nucleic Acids Research, 1996, 24, 2942-2949.	6.5	26
192	Chloroquine Resistance Is Not Associated with Drug Metabolism in Plasmodium falciparum. Journal of Parasitology, 1995, 81, 1004.	0.3	7
193	Glutathionylspermidine metabolism in Escherichia coli. Biochemical Journal, 1995, 312, 465-469.	1.7	41
194	Inhibitors of trypanothione reductase as potential antitrypanosomal drugs. Biochemical Society Transactions, 1995, 23, 511S-511S.	1.6	2
195	Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials. FEBS Journal, 1995, 230, 460-468.	0.2	21
196	Site-Directed Mutagenesis of the Redox-Active Cysteines of Trypanosoma cruzi Trypanothione Reductase. FEBS Journal, 1995, 228, 745-752.	0.2	13
197	Bimane cyclic esters, possible stereologues of trypanothione as antitrypanosomal agents. Bimanes 29. European Journal of Medicinal Chemistry, 1995, 30, 659-671.	2.6	59
198	Differential susceptibility of filarial and human erythrocyte glutathione reductase to inhibition by the trivalent organic arsenical melarsen oxide. Molecular and Biochemical Parasitology, 1995, 71, 211-219.	0.5	19

#	Article	IF	Citations
199	Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Molecular and Biochemical Parasitology, 1995, 69, 289-298.	0.5	51
200	Specificity of Ethanolamine Transport and Its Further Metabolism in Trypanosoma brucei. Journal of Biological Chemistry, 1995, 270, 16160-16166.	1.6	28
201	Uptake of Diamidine Drugs by the P2 Nucleoside Transporter in Melarsen-sensitive and -resistant Trypanosoma brucei brucei. Journal of Biological Chemistry, 1995, 270, 28153-28157.	1.6	185
202	p-(4,6-Diamino-s-triazin-2-yl)aminophenylarsonic Acid Dihydrate. Acta Crystallographica Section C: Crystal Structure Communications, 1995, 51, 1953-1955.	0.4	0
203	Site-Directed Mutagenesis of the Redox-Active Cysteines of Trypanosoma cruzi Trypanothione Reductase. FEBS Journal, 1995, 228, 745-752.	0.2	63
204	Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials. FEBS Journal, 1995, 230, 460-468.	0.2	106
205	Assessment of the polyamine metabolism of filarial worms as a target for chemotherapy. Parasite, 1994, 1, S60-S61.	0.8	0
206	Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution. Antimicrobial Agents and Chemotherapy, 1994, 38, 1298-1302.	1.4	29
207	Rational design of peptide-based inhibitors of trypanothione reductase as potential antitrypanosomal drugs. Amino Acids, 1994, 6, 295-299.	1.2	23
208	High-performance liquid chromatographic method for the separation and quantitative estimation of anti-parasitic melaminophenyl arsenical compounds. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 357-359.	0.7	5
209	The structure, organization, and expression of the Leishmania donovani gene encoding trypanothione reductase. Molecular and Biochemical Parasitology, 1994, 64, 293-301.	0.5	38
210	Structure of trypanothione reductase from Crithidia fasciculata at 2.6 Ã... resolution; enzymeâ€“NADP interactions at 2.8 Ã... resolution. Acta Crystallographica Section D: Biological Crystallography, 1994, 50, 139-154.	2.5	343
211	Identification and Biosynthesis of N1,N9-Bis(Glutathionyl)Aminopropylcadaverine (Homotrypanothione) in Trypanosoma Cruzi. FEBS Journal, 1994, 226, 1019-1027.	0.2	72
212	Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. FEBS Journal, 1994, 221, 285-295.	0.2	85
213	FC4 glutathionylspermidine synthethase from Crithidia fasciculata: Kinetic properties of glutathione and spermidine analogues. European Journal of Pharmaceutical Sciences, 1994, 2, 101.	1.9	0
214	Synthesis and antitrypanosomal evaluation of some thiazole-containing amino acids and peptides. European Journal of Medicinal Chemistry, 1993, 28, 387-397.	2.6	9
215	Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature, 1993, 361, 173-176.	13.7	339
216	Substrate interactions between trypanothione reductase and N1-glutathionylspermidine disulphide at 0.28-nm resolution. FEBS Journal, 1993, 213, 67-75.	0.2	103

#	Article	IF	Citations
217	Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. FEBS Journal, 1993, 218, 29-37.	0.2	69
218	The glutamyl binding site of trypanothione reductase from Crithidia fasciculata: enzyme kinetic properties of Î³-glutamyl-modified substrate analogues. BBA - Proteins and Proteomics, 1993, 1203, 93-98.	2.1	10
219	Cytochrome P450 in trypanosomatids. Biochemical Pharmacology, 1993, 46, 149-157.	2.0	11
220	Trypanosoma cruzi Trypanothione Reductase Crystallization, Unit Cell Dimensions and Structure Solution. Journal of Molecular Biology, 1993, 232, 1217-1220.	2.0	10
221	Polyamine and pentamidine metabolism in African trypanosomes. Acta Tropica, 1993, 54, 215-224.	0.9	26
222	Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochemical Journal, 1992, 286, 9-11.	1.7	158
223	Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology, 1992, 105, S71-S78.	0.7	33
224	Metabolism and Functions of Trypanothione in the Kinetoplastida. Annual Review of Microbiology, 1992, 46, 695-729.	2.9	714
225	Active site of trypanothione reductase. Journal of Molecular Biology, 1992, 227, 322-333.	2.0	129
226	Purification of glutathionylspermidine and trypanothione synthetases from crithidia fasciculata. Protein Science, 1992, 1, 874-883.	3.1	66
227	Molecular characterization of the trypanothione reductase gene from Crithidia fasciculata and Trypanosoma brucei: comparison with other flavoprotein disulphide oxidoreductases with respect to substrate specificity and catalytic machanism. Molecular Microbiology, 1992, 6, 3089-3099.	1.2	48
228	Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Molecular and Biochemical Parasitology, 1992, 53, 213-222.	0.5	91
229	The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei brucei. Molecular and Biochemical Parasitology, 1992, 53, 223-231.	0.5	33
230	Purification of glutathione reductase from muscle of the adult parasitic nematode Ascaris suum. Molecular and Biochemical Parasitology, 1992, 51, 331-333.	0.5	6
231	Subcellular distribution of trypanothione reductase in bloodstream and procyclic forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1991, 48, 109-112.	0.5	40
232	Inhibition of polyamine biosynthesis in Crithidia fasciculata by d,l-Î±-difluoromethylornithine and d,l-Î±-difluoromethylarginine. Molecular and Biochemical Parasitology, 1991, 46, 35-43.	0.5	15
233	Synthesis of N-benzyloxycarbonyl-l-cysteinylglycine 3-dimethylaminopropylamide disulfide: A cheap and convenient new assay for trypanothione reductase. Analytical Biochemistry, 1991, 198, 212-216.	1.1	48
234	The trypanothione reductase gene of Leishmania donovani. Biochemical Society Transactions, 1990, 18, 869-870.	1.6	5

#	Article	IF	Citations
235	Trypanothione metabolism and rational approaches to drug design. Biochemical Society Transactions, 1990, 18, 717-720.	1.6	27
236	The interaction of trypanocidal drugs with polyamine and trypanothione metabolism. Biochemical Society Transactions, 1990, 18, 1094-1096.	1.6	6
237	Future prospects for the chemotherapy of human trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 613-617.	0.7	46
238	Separation and quantitation of the polyamine biosynthesis inhibitor d,l-Î±-difluoromethylarginine and other guanidine-containing compounds by high-performance liquid chromatography. Analytical Biochemistry, 1990, 190, 281-285.	1.1	5
239	Biosynthesis of the trypanosomatid metabolite trypanothione: purification and characterization of trypanothione synthetase from Crithidia fasciculata. Biochemistry, 1990, 29, 3924-3929.	1.2	42
240	Initiating a crystallographic study of trypanothione reductase. Journal of Molecular Biology, 1990, 216, 235-237.	2.0	22
241	Novel biochemical pathways in parasitic protozoa. Parasitology, 1989, 99, S93-S112.	0.7	116
242	Trypanothione is the primary target for arsenical drugs against African trypanosomes.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 2607-2611.	3.3	184
243	Metabolism and Functions of Trypanothione with Special Reference to Leishmaniasis. , 1989, , 487-494.		2
244	Inhibition of Leishmania Species by Î±-Difluoromethylornithine. , 1989, , 749-756.		6
245	"Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 5374-5378.	3.3	169
246	The Role of Glutathionylspermidine and Trypanothione in Regulation of Intracellular Spermidine Levels During Growth of Crithidia Fasciculata. Advances in Experimental Medicine and Biology, 1988, 250, 667-674.	0.8	4
247	Trypanothione metabolism: a chemotherapeutic target in trypanosomatids. Parasitology Today, 1987, 3, 312-315.	3.1	40
248	Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata. Biochemistry, 1987, 26, 3023-3027.	1.2	96
249	Biochemical changes associated with Î±-difluoromethylornithine uptake and resistance in Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 25, 227-238.	0.5	64
250	In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 24, 185-191.	0.5	169
251	Trypanothione dependent peroxide metabolism in Crithidia fasciculata and Trypanosoma brucei. Molecular and Biochemical Parasitology, 1987, 24, 39-45.	0.5	100
252	Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme. FEBS Journal, 1987, 164, 123-128.	0.2	173

#	Article	IF	Citations
253	Synthesis of the trypanosomatid metabolites trypanothione, and N 1-mono- and N 8-mono-glutathionylspermidine. Journal of the Chemical Society Chemical Communications, 1986, , 593.	2.0	24
254	Purification and characterization of trypanothione reductase from Crithidia fasciculata, a new member of the family of disulfide-containing flavoprotein reductases. Biochemistry, 1986, 25, 3519-3526.	1.2	282
255	The biosynthesis of trypanothione and N1-glutathionylspermidine in Crithidia fasciculata. Molecular and Biochemical Parasitology, 1986, 21, 247-257.	0.5	59
256	Carbohydrate Metabolism in African Trypanosomes, with Special Reference to the Glycosome. , 1986, , 183-224.		79
257	An improved technique for the cultivation of Plasmodium falciparum in vitro without daily medium change. Annals of Tropical Medicine and Parasitology, 1985, 79, 379-384.	1.6	77
258	Identification of a novel, thiol-containing co-factor essential for glutathione reductase enzyme activity in trypanosomatids. Molecular and Biochemical Parasitology, 1985, 14, 187-198.	0.5	141
259	Transport of ethanolamine and its incorporation into the variant surface glycoprotein of bloodstream forms of Trypanosoma brucei. Molecular and Biochemical Parasitology, 1985, 15, 245-256.	0.5	30
260	Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. Science, 1985, 227, 1485-1487.	6.0	657
261	A simple magnetic method for the purification of malarial pigment. Molecular and Biochemical Parasitology, 1984, 12, 307-312.	0.5	21
262	Lipoprotein lipase suppression in 3T3â€Ł1 cells by a haematoprotozoanâ€induced mediator from peritoneal exudate cells. Parasite Immunology, 1984, 6, 203-209.	0.7	52
263	Biochemistry of trypanosomiasis and rational approaches to chemotherapy. Trends in Biochemical Sciences, 1982, 7, 249-253.	3.7	40
264	An improved method for the estimation of suramin in plasma and trypanosome samples. Molecular and Biochemical Parasitology, 1980, 1, 307-313.	0.5	4
265	Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. Molecular and Biochemical Parasitology, 1980, 1, 315-333.	0.5	96
266	Trypanosoma brucei: Maintenance of concentrated suspensions of bloodstream trypomastigotes in vitro using continuous dialysis for measurement of endocytosis. Experimental Parasitology, 1980, 49, 366-380.	0.5	29
267	Isolation and characterization of kinetoplast DNA from bloodstream form of Trypanosoma brucei.. Journal of Cell Biology, 1978, 76, 293-309.	2.3	140
268	Characterization of kinetoplast DNA networks from the insect trypanosome Crithidia luciliae. Nucleic Acids and Protein Synthesis, 1977, 478, 167-179.	1.7	24
269	Trypanosoma brucei: Suramin and other trypanocidal compounds' effects on sn-glycerol-3-phosphate oxidase. Experimental Parasitology, 1977, 43, 353-361.	0.5	49
270	New approach to screening drugs for activity against African trypanosomes. Nature, 1977, 265, 270-271.	13.7	106

#	Article	IF	Citations
271	The isolation and characterisation of particulate sn-glycerol-3-phosphate oxidase from Trypanosoma brucei. International Journal of Biochemistry & Cell Biology, 1977, 8, 659-668.	0.8	37
272	Inhibitor studies on particulate sn-glycerol-3-phosphate oxidase from Trypanosoma brucei. International Journal of Biochemistry & Cell Biology, 1977, 8, 669-675.	0.8	28